Skip to content

Effect of Lianhua Qingwen granules/capsules on patients infected with the novel coronavirus: a multicenter, retrospective cohort study

Effect of Lianhua Qingwen granules/capsules on patients infected with the novel coronavirus: a multicenter, retrospective cohort study

Status
Active, not recruiting
Phases
Phase 2
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2023000040
Enrollment
Unknown
Registered
2023-09-03
Start date
2022-08-31
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Sponsors

Jiujiang Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Asymptomatic infections and mild confirmed cases of the new coronavirus in accordance with the Diagnosis and Treatment Protocol of the Novel Coronavirus Pneumonia (Trial Version 9) after etiological testing; 2. Age = 18 years old, male or female.

Exclusion criteria

Exclusion criteria: 1. The nucleic acid test is positive, and the patient is diagnosed as common type, severe type, or critical type; 2. Patients were nucleic acid-negative. 3. Patients were taking Chinese patent medicine such as Huashi Baidu Granules, Jinhua Qinggan Granules, Xuanfei Baidu Granules, and Chinese herbal decoctions such as Qinghua PiHui prescription, Fuzheng Huazhuo prescription, Puping Qinghua prescription at the same time.

Design outcomes

Secondary

MeasureTime frame
negative time of nucleic acid test;length of hospital stay;

Primary

MeasureTime frame
negative conversion rate of nucleic acid within 7 days;

Countries

China

Contacts

Public ContactHongze Wu

Jiujiang Hospital of Traditional Chinese Medicine

whzzyy@163.com18970256865

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026